Carr, Prudence R.
Webb, Katherine L.
Neumann, Johannes T.
Thao, Le T. P.
Beilin, Lawrence J.
Ernst, Michael E.
Fitzgibbon, Bernadette
Gasevic, Danijela
Nelson, Mark R.
Newman, Anne B.
Orchard, Suzanne G.
Owen, Alice
Reid, Christopher M.
Stocks, Nigel P.
Tonkin, Andrew M.
Woods, Robyn L.
McNeil, John J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Associations of body size with all-cause and cause-specific mortality in healthy older adults
https://doi.org/10.1038/s41598-023-29586-w
Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly
https://doi.org/10.1161/hypertensionaha.120.16209
Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population
https://doi.org/10.1161/strokeaha.120.033670
Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older
https://doi.org/10.1161/circgen.121.003429
CKD Biomarkers, Cognitive Impairment, and Incident Dementia in an Older Healthy Cohort
https://doi.org/10.34067/kid.0005672021
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial
https://doi.org/10.1136/gutjnl-2020-321585
Protective lipid-lowering variants in healthy older individuals without coronary heart disease
https://doi.org/10.1136/openhrt-2021-001710
AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol
https://doi.org/10.1136/bmjopen-2016-013636
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (NE 2165/1-1)
National Health and Medical Research Council (GNT 1136372, 334047, 1127060)
National Institutes of Health (U01AG029824, U19AG062682)
Monash University
Victorian Cancer Agency
Article History
Received: 13 July 2022
Accepted: 7 February 2023
First Online: 7 March 2023
Competing interests
: J.T.N. has received honoraria from Roche and Siemens Healthinieers. A.M.T has received honoraria from Amgen, Boehinger-Ingelheim, Merck, Novartis and Pfizer. All other authors declare no conflicts of interest.